Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06366672 · ClinicalTrials.gov registry record · Early Phase 1
Evaluating the Human Immune Response to the JYNNEOS Vaccine
A Early Phase 1 study of Virus Diseases and Vaccinia, sponsored by Washington University School of Medicine.
- Active
- Registry status
- Early Phase 1
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT06366672 is a Early Phase 1 study of Virus Diseases and Vaccinia that is active but no longer recruiting, run by Washington University School of Medicine. The registered enrollment target is 20 participants, below the 1,522-participant average among 7 other Virus Diseases trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06366672, a Early Phase 1 study of Virus Diseases and Vaccinia, is active but no longer recruiting, sponsored by Washington University School of Medicine.
- ACTIVE NOT RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is designed to evaluate the magnitude and duration of the human adaptive immune response to the JYNNEOS Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) vaccine in the blood, lung mucosa, skin and bone marrow.
Conditions Studied
Interventions
- PROCEDURE Phlebotomy
- PROCEDURE Bone marrow aspiration
- PROCEDURE Skin punch biopsy
- BIOLOGICAL JYNNEOS (Smallpox and Monkeypox Vaccine, Live, Nonreplicating) suspension for subcutaneous injection
- PROCEDURE Research bronchoscopy
Study Locations (1)
Missouri
- Washington University in Saint Louis School of Medicine Emergency Care and Research Core - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2024-06-10 |
| Est. Completion | 2026-12 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06366672
The ClinicalTrials.gov registry entry for NCT06366672 describes a study currently listed as active not recruiting, categorized as Early Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,522-participant average among 7 other Virus Diseases trials with a reported enrollment target (99% lower). The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Virus Diseases appearing as the primary indexed condition, and to 5 interventions - of which Phlebotomy is the first listed.
NCT06366672 reports 1 study location spanning 1 distinct geographic area - top geographies include Missouri.
Frequently Asked Questions
What is clinical trial NCT06366672 about?
NCT06366672 is a clinical study titled "Evaluating the Human Immune Response to the JYNNEOS Vaccine". This study is designed to evaluate the magnitude and duration of the human adaptive immune response to the JYNNEOS Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) vaccine in the blood, lung mucosa, skin and bone marrow.
What is the current status of trial NCT06366672?
This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 20 participants. The study started on 2024-06-10. Estimated completion is 2026-12.
What conditions does trial NCT06366672 study?
This clinical trial studies the following conditions: Virus Diseases, Vaccinia.
What interventions are being tested in trial NCT06366672?
The interventions under investigation include: Phlebotomy (PROCEDURE), Bone marrow aspiration (PROCEDURE), Skin punch biopsy (PROCEDURE), JYNNEOS (Smallpox and Monkeypox Vaccine, Live, Nonreplicating) suspension for subcutaneous injection (BIOLOGICAL), Research bronchoscopy (PROCEDURE).
Who is sponsoring clinical trial NCT06366672?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06366672 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Virus Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Convalescent Plasma Collection and Treatment in Pediatrics and Adults
RECRUITING · Phase 3
-
Bevacizumab in Adults With Recurrent Respiratory Papillomatosis (RRP)
ACTIVE NOT RECRUITING · Phase 2
-
Safety of and Immune Response to a Bird Flu Virus Vaccine (H9N2) in Healthy Adults (Study A)
COMPLETED · Phase 1
-
A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Experimental Rabies Vaccine in Healthy Adults
COMPLETED · Phase 1
-
Safety and Immune Response to Recombinant Live-Attenuated Influenza H2N2 Virus Vaccine
COMPLETED · Phase 1
-
Efficacy, Safety, and Immunogenicity of a Plant-Derived Quadrivalent Virus-Like Particles (VLPs) Influenza Vaccine in Adults
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.